Dysbiosis Index: Developing a Quantitative Tool for Assessing Gut Microbiota Imbalance

Hosfat Armel^*
*Correspondence: Hosfat Armel, Department of Pathology, Leiden Medical University, Leiden, Netherlands, Email:

Introduction

The human gut microbiota is a diverse and dynamic ecosystem that plays a crucial role in maintaining host health, influencing everything from digestion and metabolism to immune regulation and neurodevelopment [1]. A balanced microbial community is essential for homeostasis, but this equilibrium is easily disrupted by factors such as antibiotic use, poor diet, infection, and chronic disease. This state of microbial imbalance, termed dysbiosis, has been implicated in a wide range of conditions, including Inflammatory Bowel Disease (IBD), metabolic syndrome, neuropsychiatric disorders, and colorectal cancer. Despite its clinical relevance, the assessment of dysbiosis remains largely qualitative or based on indirect indicators, limiting its utility in diagnostics and longitudinal monitoring. To address this gap, there is a growing need for a standardized, quantitative tool that can objectively measure the extent of gut microbial imbalance and serve as a biomarker for disease risk, progression, or response to therapy [2].

Description

This study focuses on the development and validation of a Dysbiosis Index (DI)â??a numerical score derived from microbial community data that quantifies the degree of gut microbiota deviation from a healthy reference state. Using a large dataset of 16S rRNA gene sequencing profiles from both healthy individuals and patients with various dysbiosis-associated conditions, we employed machine learning and statistical modeling to identify microbial signatures most predictive of dysbiotic states. Key features include reductions in beneficial taxa such as Faecalibacterium prausnitzii, Bifidobacterium spp., and Akkermansia muciniphila, alongside overrepresentation of pro-inflammatory or pathogenic bacteria such as Escherichia coli, Enterococcus faecalis, and Clostridium difficile. These features were integrated into a weighted scoring algorithm that calculates a continuous DI, with higher values indicating greater degrees of dysbiosis [3].

The DI was validated across multiple independent cohorts, including patients with IBD, Irritable Bowel Syndrome (IBS), obesity, and post-antibiotic dysbiosis, showing strong correlation with disease severity, inflammatory biomarkers, and symptom burden. In prospective studies, changes in the DI reflected clinical responses to interventions such as probiotics, dietary modifications, and Fecal Microbiota Transplantation (FMT), demonstrating its potential for monitoring therapeutic outcomes. Additionally, in healthy individuals, the DI remained relatively stable over time, suggesting it can serve as a reliable baseline for detecting deviations. Receiver Operating Characteristic (ROC) analysis confirmed the indexâ??s high sensitivity and specificity in distinguishing dysbiotic from eubiotic states, supporting its utility as a diagnostic and prognostic tool [4,5].

Conclusion

In conclusion, the Dysbiosis Index represents a novel and robust quantitative metric for assessing gut microbiota imbalance. By translating complex microbial data into an interpretable score, the DI offers a standardized method to evaluate dysbiosis in clinical and research settings. Its application has the potential to enhance patient stratification, guide microbiome-targeted therapies, and improve our understanding of the role of gut microbiota in human disease. As precision medicine increasingly incorporates microbiome insights, tools like the DI will be instrumental in bridging microbial ecology with clinical decision-making.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Leylabadlo, Hamed Ebrahimzadeh, Reza Ghotaslou, Mohammad Mehdi Feizabadi and Safar Farajnia, et al. "The critical role of Faecalibacterium prausnitzii in human health: An overview." Microb Pathog 149 (2020): 104344.

Google Scholar Cross Ref Indexed at

2. Mah, Cassandra, Thisun Jayawardana, Gary Leong and Sabrina Koentgen, et al. "Assessing the relationship between the gut microbiota and inflammatory bowel disease therapeutics: A systematic review." Pathogens 12 (2023): 262.

Google Scholar Cross Ref Indexed at

3. Feng, Cuijiao, Weiqin Zhang, Tao Zhang and Qiuwen He, et al. "Heat-killed Bifidobacterium bifidum B1628 may alleviate dextran sulfate sodium-induced colitis in mice and the anti-inflammatory effect is associated with gut microbiota modulation." Nutrients 14 (2022): 5233.

Google Scholar Cross Ref

4. Baldelli, Valerio, Franco Scaldaferri, Lorenza Putignani and Federica Del Chierico. "The role of Enterobacteriaceae in gut microbiota dysbiosis in inflammatory bowel diseases." Microorganisms 9 (2021): 697.

Google Scholar Cross Ref Indexed at

5. Cosnes, Jacques, Corinne Gower–Rousseau, Philippe Seksik and Antoine Cortot. "Epidemiology and natural history of inflammatory bowel diseases." Gastroenterology 140 (2011): 1785-1794.

Google Scholar Cross Ref